Abstract
α-Difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase, inhibited B16 melanoma-induced angiogenesis in chick embryo chorioallantoic membrane and subsequently the growth of the tumor on the chorioallantoic membrane. These inhibitions were reversed by exogenous putrescine and spermidine. DFMO also inhibited rapid neovascularization in yolk sac membrane of 4-day-old chick embryos and the inhibition was reversed by exogenous putrescine and spermidine. DFMO strongly inhibited DNA synthesis and proliferation of bovine pulmonary artery endothelial (BPAE) cells in culture and decreased their ornithine decarboxylase activity and intracellular polyamine concentrations. Addition of putrescine to the culture medium of DFMO-treated BPAE cells restored their intracellular putrescine and spermidine concentrations and their DNA synthesis and proliferation. Addition of spermidine to cultures of DFMO-treated BPAE cells restored their intracellular spermidine concentration and their DNA synthesis and proliferation. DFMO inhibited the proliferation of B16 melanoma cells in culture but the inhibitory effect was much less than that on BPAE cells. When one-half the monolayer of confluent cultures of BPAE cells had been peeled off, addition of DFMO to the cultures inhibited the proliferation and extension of the BPAE cells into the vacant area but had no effect on stationary cells in the remaining half of the monolayer, suggesting that it inhibited induction of proliferation of endothelial cells. These findings suggest that the antitumor activity of DFMO against solid tumors is probably due more to its inhibition of tumor-induced angiogenesis by inhibition of proliferation of endothelial cells induced by polyamine depletion than to a direct effect on tumor cell proliferation.
Footnotes
-
↵1 This paper is dedicated to Dr. R. K. Boutwell on the occasion of his retirement from the University of Wisconsin.
-
↵2 Supported in part by Grants-in-Aid for Scientific Research (to M. T. and F. S.) and Developmental Scientific Research (to M. T.) from the Ministry of Education, Science and Culture of Japan, and Kudo Scientific Foundation (to M. T.), the Kowa Life Science Foundation (to M. T.), the Research Foundation for Cancer and Cardiovascular Diseases (to M. T.), and the Osaka Anti-Cancer Society (to M. T. and M. E.).
-
↵3 To whom requests for reprints should be addressed.
- Received July 12, 1989.
- Revision received February 19, 1990.
- ©1990 American Association for Cancer Research.